Study of a new tricuspid valve replacement for severe leakage
Part of Heart & circulation clinical trials.
This study tests a new, less invasive way to replace the tricuspid valve (the valve between the right upper and lower heart chambers) in people with severe leakage. The valve is delivered through a vein in the neck or leg, avoiding open-heart surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have symptoms from a leaky tricuspid valve (tricuspid regurgitation) despite being on heart medications for at least 30 days.
- Your leaky valve is classified as severe, massive, or torrential on an echocardiogram.
- A heart team and a patient selection committee agree you are a good candidate for this procedure.
- Your heart structure is suitable for the Laplace valve device, which can be placed through a vein in your neck or leg.
- You are willing to sign a consent form and come back for all follow-up visits after the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a catheter-based procedure (done through the blood vessels) to repair a severely leaky tricuspid valve. It may help people with symptoms or past hospitalizations from tricuspid valve leakage who are higher-risk for standard surgery.
This trial tests a new device called Laplace TTVR to replace a leaky tricuspid valve in the heart without open surgery. It is for people with severe symptoms despite medical treatment.
This study tests a new, catheter-based procedure to treat moderate-to-severe leaking of the tricuspid valve (a heart valve on the right side). It’s for people who are high surgical risk and might benefit from replacing the valve without open-heart surgery.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study tests a new catheter-based device to repair a leaky tricuspid heart valve (tricuspid regurgitation) in people who still have symptoms like shortness of breath or swelling despite taking heart medications. The goal is to see if the procedure is safe and can help reduce the leak.
This trial tests a new device called the Medtronic Intrepid TTVR system to replace the tricuspid valve in people with severe tricuspid regurgitation (leaky valve). It aims to see if the device can safely and effectively fix the leak and improve symptoms.
Hear when a new Tricuspid Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.